IRIS – Institutional Research Information System
IRIS è il sistema di gestione della ricerca dell’Università degli Studi di Milano-Bicocca.Il repository BOA è il modulo del sistema dedicato alla raccolta e alla disseminazione della produzione scientifica di Ateneo. Le pubblicazioni sono ricercabili per parola chiave attraverso il box nella barra orizzontale in alto oppure, mediante il pulsante Sfoglia, per "Afferenza", "Autore", "Titolo", "Tipologia" o "Settore scientifico-disciplinare".
IRIS contiene inoltre alcuni moduli dedicati alla registrazione dei progetti e dei contratti, e alla reportistica avanzata per le attività di valutazione della ricerca
EnglishBody mass index (BMI) is a main indicator of obesity and its association with breast cancer is well established. However, little is known in the metastatic setting, especially in HER2-positive patients. We assessed the influence of BMI on clinical outcomes of patients treated with pertuzumab and/or trastuzumab emtansine (T-DM1) for HER2+ metastatic breast cancer (mBC). BMI was addressed as a categorical variable, being classified on the basis of the following ranges, that is, 18.5–24.9, 25–29.9, and 30.0–34.9, namely, normal weight, overweight, and Class I obesity. The outcomes chosen were progression-free survival to first-line chemotherapy (PFS1) and overall survival (OS). Overall (N = 709), no impact of BMI was observed on PFS1 (p =.15), while BMI ≥ 30 was associated with worse OS (p =.003). In subjects who progressed to first line (N = 575), analyzing data across PFS1 quartiles and strata of disease burden, BMI predicted lower PFS1 in patients within the I PFS1 quartile and with the lowest disease burden (p =.001). Univariate analysis showed a detrimental effect of BMI ≥ 30 on OS for women within the I PFS1 quartile (p =.03). Results were confirmed in multivariate analysis. According to PFS1 quartiles a higher percentage of patients with high BMI and low disease burden progressed within 6 months of therapy. The effect of BMI on prognosis was also confirmed in multivariate analysis of OS for overall population. In our cohort, a BMI ≥ 30 correlated with worse OS in patients with HER2+ mBC who received pertuzumab and/or T-DM1 but had no impact on PFS to first line. BMI predicted worse I PFS1 quartile.
Krasniqi, E., Pizzuti, L., Barchiesi, G., Sergi, D., Carpano, S., Botti, C., et al. (2020). Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. JOURNAL OF CELLULAR PHYSIOLOGY, 235(11), 7900-7910 [10.1002/jcp.29445].
| Citazione: | Krasniqi, E., Pizzuti, L., Barchiesi, G., Sergi, D., Carpano, S., Botti, C., et al. (2020). Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. JOURNAL OF CELLULAR PHYSIOLOGY, 235(11), 7900-7910 [10.1002/jcp.29445]. | |
| Tipo: | Articolo in rivista - Articolo scientifico | |
| Carattere della pubblicazione: | Scientifica | |
| Presenza di un coautore afferente ad Istituzioni straniere: | No | |
| Titolo: | Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence | |
| Autori: | Krasniqi, E; Pizzuti, L; Barchiesi, G; Sergi, D; Carpano, S; Botti, C; Kayal, R; Sanguineti, G; Marchetti, P; Botticelli, A; Marinelli, D; Gamucci, T; Natoli, C; Grassadonia, A; Tinari, N; Tomao, S; Tonini, G; Santini, D; Michelotti, A; Mentuccia, L; Vaccaro, A; Magnolfi, E; Gelibter, A; Magri, V; Cortesi, E; D'Onofrio, L; Cassano, A; Cazzaniga, M; Moscetti, L; Fabbri, A; Scinto, A; Corsi, D; Carbognin, L; Bria, E; La Verde, N; Garufi, C; Di Stefano, P; Mirabelli, R; Veltri, E; Paris, I; Giotta, F; Lorusso, V; Landucci, E; Ficorella, C; Roselli, M; Adamo, V; Ricciardi, G; Russo, A; Valerio, M; Berardi, R; Pistelli, M; Cannita, K; Zamagni, C; Garrone, O; Baldini, E; Livi, L; Meattini, I; Del Medico, P; Generali, D; De Maria, R; Risi, E; Ciliberto, G; Villa, A; Sperduti, I; Mazzotta, M; Barba, M; Giordano, A; Vici, P | |
| Autori: | ||
| Data di pubblicazione: | 2020 | |
| Lingua: | English | |
| Rivista: | JOURNAL OF CELLULAR PHYSIOLOGY | |
| Digital Object Identifier (DOI): | http://dx.doi.org/10.1002/jcp.29445 | |
| Appare nelle tipologie: | 01 - Articolo su rivista |
File in questo prodotto:
| File | Descrizione | Tipologia | Licenza | |
|---|---|---|---|---|
| Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and:or trastuzumab .pdf | Articolo principale | Publisher's version | Administrator Richiedi una copia |
Copyright © 2021